407 related articles for article (PubMed ID: 32063100)
21. The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population.
Hathway JM; Miller-Wilson LA; Sharma A; Jensen IS; Yao W; Raza S; Parks PD; Weinstein MC
J Mark Access Health Policy; 2021; 9(1):1948670. PubMed ID: 34512929
[No Abstract] [Full Text] [Related]
22. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
Berger BM; Schroy PC; Dinh TA
Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
24. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
25. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model.
Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ
Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894
[TBL] [Abstract][Full Text] [Related]
26. Performance of multitarget stool DNA testing in African American patients.
Cooper GS; Markowitz SD; Chen Z; Tuck M; Willis JE; Berger BM; Brenner DE; Li L
Cancer; 2018 Oct; 124(19):3876-3880. PubMed ID: 30193399
[TBL] [Abstract][Full Text] [Related]
27. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
[TBL] [Abstract][Full Text] [Related]
28. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.
Bosch LJW; Melotte V; Mongera S; Daenen KLJ; Coupé VMH; van Turenhout ST; Stoop EM; de Wijkerslooth TR; Mulder CJJ; Rausch C; Kuipers EJ; Dekker E; Domanico MJ; Lidgard GP; Berger BM; van Engeland M; Carvalho B; Meijer GA
Am J Gastroenterol; 2019 Dec; 114(12):1909-1918. PubMed ID: 31764091
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population.
Karlitz JJ; Fendrick AM; Bhatt J; Coronado GD; Jeyakumar S; Smith NJ; Plescia M; Brooks D; Limburg P; Lieberman D
Popul Health Manag; 2022 Jun; 25(3):343-351. PubMed ID: 34958279
[TBL] [Abstract][Full Text] [Related]
30. Colorectal cancer screening uptake and adherence by modality at a large tertiary care center in the United States: a retrospective analysis.
Cheney C; Parish A; Niedzwiecki D; Oko C; Walters C; Halpern D; Helmueller L; Hoyek NE; Miller-Wilson LA; Sullivan BA
Curr Med Res Opin; 2024 Mar; 40(3):431-439. PubMed ID: 38197407
[TBL] [Abstract][Full Text] [Related]
31. Serrated Polyp Yield at Colonoscopy in Patients with Positive FIT, Positive mt-sDNA, and Colonoscopy Only: Data from the New Hampshire Colonoscopy Registry.
Anderson JC; Hisey WM; Robinson CM; Limburg PJ; Kneedler BL; Butterly LF
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):226-232. PubMed ID: 36409472
[TBL] [Abstract][Full Text] [Related]
32. Colonoscopy Findings in FIT+ and mt-sDNA+ Patients versus in Colonoscopy-only Patients: New Hampshire Colonoscopy Registry Data.
Anderson JC; Robinson CM; Hisey W; Limburg PJ; Butterly LF
Cancer Prev Res (Phila); 2022 Jul; 15(7):455-464. PubMed ID: 35378546
[TBL] [Abstract][Full Text] [Related]
33. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
34. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
[TBL] [Abstract][Full Text] [Related]
35. Colorectal Neoplasia Detection in Individuals With Positive Multitarget Stool DNA Tests: Data From the New Hampshire Colonoscopy Registry.
Anderson JC; Robinson CM; Hisey WM; Edwards DK; Kneedler BL; Berger BM; Butterly LF
J Clin Gastroenterol; 2022 May-Jun 01; 56(5):419-425. PubMed ID: 33973962
[TBL] [Abstract][Full Text] [Related]
36. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.
Cross AJ; Wooldrage K; Robbins EC; Kralj-Hans I; MacRae E; Piggott C; Stenson I; Prendergast A; Patel B; Pack K; Howe R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran SP; Atkin WS
Gut; 2019 Sep; 68(9):1642-1652. PubMed ID: 30538097
[TBL] [Abstract][Full Text] [Related]
37. Quantified trends in provider reimbursement and utilization volume in colorectal cancer screenings: analysis of Medicare claims from 2000 to 2019.
Bommineni VM; Bommineni VL; Gupta R
Colorectal Dis; 2024 May; 26(5):1028-1037. PubMed ID: 38581083
[TBL] [Abstract][Full Text] [Related]
38. A novel multitarget stool DNA test for colorectal cancer screening.
Malik P
Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807
[TBL] [Abstract][Full Text] [Related]
39. Noninvasive fecal testing for colorectal cancer.
Zou J; Xiao Z; Wu Y; Yang J; Cui N
Clin Chim Acta; 2022 Jan; 524():123-131. PubMed ID: 34756863
[TBL] [Abstract][Full Text] [Related]
40. Influence of Colorectal Cancer Risk Factors on Predictive Value of a Positive Multitarget Stool DNA Test.
Narayani KR; Narayani RI
J Clin Gastroenterol; 2024 May-Jun 01; 58(5):471-474. PubMed ID: 37389965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
